Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SoloVir ETS
- Development stage
- Discontinued
- Lead developer
- Transport Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal, Topical
01
Overview
SoloVir ETS (Electrokinetic Transdermal System) is a drug-device combination product developed by Transport Pharmaceuticals for the treatment of herpes labialis (cold sores). It utilizes a proprietary iontophoretic technology to enhance the transdermal delivery of a 5% acyclovir gel formulation. The system consists of a reusable, battery-powered control unit and single-use disposable cartridges containing the medication. By applying a low-voltage electric current, the device facilitates the movement of acyclovir across the skin barrier, achieving significantly higher tissue concentrations compared to oral administration. Clinical trials demonstrated its efficacy in stopping the progression of cold sore episodes with high patient compliance. Although it showed promise in Phase 2 trials, the developer appears to have ceased operations, and the product is no longer in active development.
- Brand names
- SoloVir ETS
- Other names
- SoloVirElectrokinetic Transdermal System
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on SoloVir ETS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SoloVir ETS.